Enzalutamide is recommended by NICE .

As part of the NICE single technology appraisal process, our HTA Group critically reviewed the company’s submission related to the evidence for the clinical and cost-effectiveness of enzalutamide (trade name Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people not previously treated with chemotherapy. The submission focused on the results of a single large, international, multicentre trial of enzalutamide versus placebo. Enzalutamide is recommended, within its marketing authorisation, as an option for treating metastatic hormone‑relapsed prostate cancer: (i) in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated and (ii) only when the company provides it with the discount agreed in the patient access scheme.


Clare Robertson: c.robertson@abdn.ac.uk 


Completed; for further information see:  https://www.journalslibrary.nihr.ac.uk/programmes/hta/1313101/#/